Business Wire

QuantrolOx Unveils VIDYAQAR — the World’s First True Open-Architecture Quantum Platform for Education, Research, Testing and Benchmarking

10.12.2025 14:29:00 EET | Business Wire | Press release

Share

QuantrolOx today announced a major milestone in quantum technology with the launch of VIDYAQAR, the world’s first True Open-Architecture Quantum Platform designed specifically for education, research, testing, and benchmarking. The system was unveiled today in India and will be available globally in the first half of 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210668898/en/

VIDYAQAR - A complete quantum platform with cryogenics, control hardware and QPU - powered by Quantum EDGE.

The name VIDYAQAR derives from the Sanskrit Vidyākar, meaning “causing wisdom, giving knowledge or science”—a perfect reflection of the platform’s mission to widen access to advanced quantum hardware and accelerate innovation.

A Complete, Open and Scalable Quantum Platform

VIDYAQAR is a connected, fully open-architecture superconducting quantum system that brings together:

  • Cryogenics
  • Control electronics
  • Quantum Processing Unit (QPU)
  • Integrated Quantum EDGE software stack

Designed for organisations entering the quantum domain for the first time, VIDYAQAR enables teams to start running experiments on day one, customize every layer of the system without constraints, and scale their infrastructure over time.

This is True Open Architecture: transparent, flexible, and modular.

Why VIDYAQAR Matters

A thriving quantum ecosystem requires shared, open testbeds where hardware, software, and control methods can be prototyped, validated, and benchmarked. VIDYAQAR fills this critical gap.

The platform supports a national or institutional quantum strategy by enabling:

  • Rapid prototyping of new ideas in quantum hardware, software, and control
  • Collaboration between universities, government labs, and industry
  • Development of standards, interoperability frameworks, and indigenous capability
  • Deployment of a scalable national network of quantum systems

VIDYAQAR is built on QuantrolOx’s proven open-architecture quantum computer in Delft, already running with multiple QPUs, electronics stacks, and cryogenic components.

Built for Learning — and for Serious R&D

VIDYAQAR is not only a research powerhouse but also an ideal training environment for the next generation of quantum experts. Key features include:

  • Quantum EDGE Academy — A comprehensive training program for mastering superconducting quantum hardware
  • Python SDK — Full programmability for custom experiments, libraries, and workflows
  • Built-in automation with Quantum EDGE — Accelerates bring-up, characterization, calibration, and tuning
  • Modular scalability — Upgrade from a single system to a centrally orchestrated “system of systems”

Availability

VIDYAQAR launches today in India and will be available to customers worldwide in 1H 2026.

QuantrolOx invites universities, national research facilities, and industrial R&D labs seeking an open, extensible quantum platform to join us on the journey to quantum computing.

About QuantrolOx

QuantrolOx develops Quantum EDGE, a next-generation measurement and automation platform that supercharges quantum R&D. Quantum EDGE provides industry-leading capabilities in measurement and automation, all with a modern, polished user interface that is intuitive to use and designed to simplify the complexity of quantum hardware. It works out of the box and integrates with leading instruments. Quantum EDGE is developed and tested on real quantum setups with multiple QPUs across varying architectures - so you can trust it to work reliably in actual lab environments.

Instead of teams of PhD experts spending days manually tuning qubits, Quantum EDGE can automatically characterise and tune a 2-qubit gate in under 25 minutes, and repeat this reliably. That means thousands of development cycles per year instead of just a handful, so hardware teams can improve their qubits much faster. This rapid iteration is essential for building fault-tolerant quantum computers.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251210668898/en/

Contacts

Media Contact
QuantrolOx
Vishal Chatrath
Chief Executive Officer, QuantrolOx
Email: vishal@quantrolox.com
www.quantrolox.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.quantrolox.
com&esheet=54373398&newsitemid=20251210668898&lan=en-US&anchor=www.quantrolox.co
m&index=1&md5=40cf67e2f7aeacd1c825d4cf9cfde12f

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye